Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pimecrolimus
Drug ID BADD_D01773
Description Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Indications and Usage For treatment of mild to moderate atopic dermatitis.
Marketing Status approved; investigational
ATC Code D11AH02
DrugBank ID DB00337
KEGG ID D05480
MeSH ID C117268
PubChem ID 6447131
TTD Drug ID D0Z4UN
NDC Product Code 55486-1585; 68682-112; 62227-004; 68254-0014; 0187-5102; 0591-2944; 62227-024; 65727-045; 0187-5101; 53296-0115; 0187-5100; 68682-110; 68462-609; 68682-111; 51552-1620; 16436-0115; 0187-5103
UNII 7KYV510875
Synonyms pimecrolimus | 33-epi-chloro-33-desoxyascomycin | SDZ ASM 981 | SDZ-ASM-981 | ASM 981 | Elidel
Chemical Information
Molecular Formula C43H68ClNO11
CAS Registry Number 137071-32-0
SMILES CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C 4)OC)Cl)C)O)C)OC)OC)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Accident12.01.08.001---
Acne23.02.01.001---
Alcohol intolerance14.02.01.001--
Alopecia23.02.02.0010.000700%
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angiocentric lymphoma01.11.04.002; 16.17.04.002---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.005---
Application site irritation08.02.01.003; 12.07.01.003---
Application site pain08.02.01.004; 12.07.01.0040.001586%-
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.004---
Application site rash08.02.01.016; 12.07.01.016; 23.03.13.0080.001586%-
Application site reaction08.02.01.006; 12.07.01.006---
Arthralgia15.01.02.001--
Asthma10.01.03.010; 22.03.01.0020.000466%-
Back pain15.03.04.005--
Basal cell carcinoma16.03.02.001; 23.08.02.001---
Blister12.01.06.002; 23.03.01.0010.001586%-
Body temperature increased13.15.01.001---
Bone disorder15.02.04.004---
Bronchitis11.01.09.001; 22.07.01.001--
Burning sensation08.01.09.029; 17.02.06.0010.000466%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.0030.000466%-
Colon cancer07.21.01.001; 16.13.01.001---
Condition aggravated08.01.03.0040.000700%-
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages